ROC curve analyses indicated that the pre-treatment ratio of TMEM14C AJ/CJ was predictive of the onset of RBC TI on H3B-8800 treatment in MDS patients with an optimal Youden index J = 0.733 for an associated criterion of >4.01 with a 83.3% sensitivity and 90% specificity. This evidence concerns the gene TMEM14C and myelodysplastic syndrome.